PXR variants and artemisinin use in vietnamese subjects: Frequency distribution and impact on the interindividual variability of CYP3A induction by artemisinin

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 2153-2157

  Piedade, Rita ^a,b,c   Schaeffeler, Elke ^a   Winter, Stefan ^a   Asimus, Sara ^d   Schwab, Matthias ^a,e   Ashton, Michael ^d   Burk, Oliver ^a   Gilb, José P ^b,c,f  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF ALGARVE   (Portugal)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f BINGHAMTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMISININ; CYTOCHROME P450 3A; PREGNANE X RECEPTOR; PROTEIN VARIANT;

ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE FREQUENCY; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIET NAM;

3' UNTRANSLATED REGIONS; ALLELES; ANTIMALARIALS; ARTEMISININS; CYTOCHROME P-450 CYP3A; DNA PRIMERS; ENZYME INDUCTION; GENE FREQUENCY; GENETIC VARIATION; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, STEROID; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; VIETNAM;

EID: 84858674163     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06009-11     Document Type: Article

References (34)

1. Asimus S, et al. 2007. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects. Fundam. Clin. Pharmacol. 21:307-316. (Pubitemid 46800472)
2. Benkali K, et al. 2009. Tacrolimus population pharmacokinetic- pharmacogenetic analysis and Bayesian estimation in renal transplant recipients. Clin. Pharmacokinet. 48:805-816.
3. Bosch TM, et al. 2006. Screening for polymorphisms in the PXR gene in a Dutch population. Eur. J. Clin. Pharmacol. 62:395-399.
4. Burk O, et al. 2005. Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor. Mol. Pharmacol. 67:1954-1965. (Pubitemid 41007777)
5. D'Alessandro U. 2009. Progress in the development of piperaquine combinations for the treatment of malaria. Curr. Opin. Infect. Dis. 22:588-592.
6. di Masi A, De Marinis E, Ascenzi P, Marino M. 2009. Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol. Aspects Med. 30:297-343.
7. Djimde A, Lefevre G. 2009. Understanding the pharmacokinetics of Coartem. Malar. J. 8(Suppl. 1):S4.
8. Dring MM, et al. 2006. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130:341-348, 592.
9. Hombhanje FW, et al. 2009. Artemisinin-naphthoquine combination (ARCO) therapy for uncomplicated falciparum malaria in adults of Papua New Guinea: a preliminary report on safety and efficacy. Malar. J. 8:196.
10. Hor SY, et al. 2008. PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J. 8:139-146. (Pubitemid 351411550)
11. Hustert E, et al. 2001. Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab. Dispos. 29:1454-1459. (Pubitemid 33000692)
12. Ivanova R, et al. 1999. Mitochondrial DNA polymorphism in the Vietnamese population. Eur. J. Immunogenet. 26:417-422.
13. Karlsen TH, et al. 2006. Polymorphisms in the steroid and xenobiotic receptor gene influence survival in primary sclerosing cholangitis. Gastroenterology 131:781-787. (Pubitemid 44307062)
14. Kerb R, et al. 2009. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect. Dis. 9:760-774.
15. Kimchi-Sarfaty C, et al. 2007. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315:525-528. (Pubitemid 46175758)
16. King CR, et al. 2007. Identification of NR1I2 genetic variation using resequencing. Eur. J. Clin. Pharmacol. 63:547-554. (Pubitemid 46684492)
17. Komar AA. 2007. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 8:1075-1080. (Pubitemid 47423694)
18. Lacher M, et al. 2009. Nuclear pregnane X receptor single nucleotide polymorphism (-25385C/T) is not associated with inflammatory bowel disease in pediatric patients. J. Pediatr. Gastroenterol. Nutr. 49:147-150.
19. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E. 2008. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab. Dispos. 36:169-181.
20. Martínez A, et al. 2007. Role of the PXR gene locus in inflammatory bowel diseases. Inflamm. Bowel Dis. 13:1484-1487.
21. Oleson L, von Moltke LL, Greenblatt DJ, Court MH. 2010. Identification of polymorphisms in the 3=-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism. Xenobiotica 40:146-162.
22. Oliver P, Lubomirov R, Carcas A. 2010. Genetic polymorphisms of CYP1A2, CYP3A4, CYP3A5, pregnane/steroidXreceptor and constitutive androstane receptor in 207 healthy Spanish volunteers. Clin. Chem. Lab. Med. 48:635-639.
23. Op den Buijsch RA, et al. 2005. Genotyping of the PXR A11156C polymorphism with locked nucleic acid containing fluorogenic probes. Pharmacogenomics J. 5:72-74. (Pubitemid 40468112)
24. Piedade R, Gil JP. 2011. The pharmacogenetics of antimalaria artemisinin combination therapy. Expert Opin. Drug Metab. Toxicol. 7:1185-1200.
25. Sandanaraj E, et al. 2008. PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin. Cancer Res. 14:7116-7126.
26. Siccardi M, et al. 2008. Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C→T) with reduced concentrations of unboosted atazanavir. Clin. Infect. Dis. 47:1222-1225.
27. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. 2009. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst. Rev. 2011:CD007483.
28. Sookoian S, et al. 2010. The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease. Pharmacogenet. Genomics 20:1-8.
29. Tham LS, et al. 2007. Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin. Cancer Res. 13:7126-7132.
30. Tshefu AK, et al. 2010. Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial. Lancet 375:1457-1467.
31. Tun T, et al. 2009. Efficacy of oral single dose therapy with artemisinin-naphthoquine phosphate in uncomplicated falciparum malaria. Acta Trop. 111:275-278.
32. Veiga MI, et al. 2009. Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam. Eur. J. Clin. Pharmacol. 65:355-363.
33. Wang XD, et al. 2008. Single nucleotide polymorphisms of the pregnane x receptor gene in Han Chinese and a comparison with other ethnic populations. Pharmacology 81:350-354.
34. Zhang J, et al. 2001. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11:555-572. (Pubitemid 32953582)